Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DNA vaccines: development, standardization and regulation.

K Cichutek1

  • 1Department of Medical Biotechnology, Paul-Ehrlich-Institut, Langen, Germany. cickl@pei.de

Intervirology
|March 17, 2001
PubMed
Summary

Nucleic acid vaccines utilize nonvectored nucleic acids for prophylactic vaccination in humans and animals. Regulatory frameworks in Europe support their development and clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Special considerations for the regulation of biological medicinal products in individualised medicine. More than stratified medicine].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·2013
Same author

RNAi-mediated gene silencing in tumour tissue using replication-competent retroviral vectors.

Gene therapy·2011
Same author

Relevance of an academic GMP Pan-European vector infra-structure (PEVI).

Current gene therapy·2010
Same author

[The framework is established: progress in gene therapy, cell therapy and tissue engineering medicine].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·2010
Same author

Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity.

Gene therapy·2009
Same author

Cell entry targeting restricts biodistribution of replication-competent retroviruses to tumour tissue.

Gene therapy·2008

Area of Science:

  • Vaccinology
  • Molecular biology
  • Public health

Background:

  • Nucleic acid vaccines represent a novel class of prophylactic vaccines.
  • Existing guidelines from organizations like the WHO address DNA vaccine quality.
  • Ongoing development focuses on manufacturing and preclinical testing standards.

Purpose of the Study:

  • To outline the regulatory landscape for nucleic acid vaccine development.
  • To highlight the established safety assessments preceding human trials.
  • To confirm the legal provisions for clinical testing and licensing in Europe.

Main Methods:

  • Review of existing WHO guidelines for DNA vaccines.
  • Analysis of theoretical risks and their assessment.
  • Examination of legal requirements for clinical trials and licensing in Germany and EU member states.

Main Results:

  • Nucleic acid vaccines are defined by their nonvectored nucleic acid composition.
  • Standards for manufacture and preclinical testing are under development.
  • Legal frameworks in Germany and the EU permit clinical trials and licensing.

Conclusions:

  • Nucleic acid vaccines are being developed under established safety and regulatory protocols.
  • European legal requirements facilitate the advancement of these novel vaccines.
  • The development pathway for nucleic acid vaccines is supported by regulatory oversight.

Related Experiment Videos